UDR Declares Quarterly Dividend

DENVER--(BUSINESS WIRE)-- UDR, Inc. (NYSE: UDR), a leading multifamily real estate investment trust, today announced that its Board of Directors declared a regular quarterly dividend on its common stock for the first quarter of 2023 in the amount of $0.42 per share, payable in cash on May 1, 2023 to UDR common stock shareholders of record as of April 10, 2023. The May 1, 2023 dividend will be the 202nd consecutive quarterly dividend paid by the Company on its common stock.

As previously disclosed in February, the Company’s annualized common dividend of $1.68 per share in 2023 represents a 10.5% increase over the annualized common dividend of $1.52 per share in 2022.

UDR also announced that its Board of Directors declared a regular quarterly dividend on its Series E preferred stock for the first quarter of 2023 in the amount of $0.4548 per share. The preferred dividend is payable on May 1, 2023 to Series E preferred stock shareholders of record as of April 10, 2023.

About UDR, Inc.

UDR, Inc. (NYSE: UDR), an S&P 500 company, is a leading multifamily real estate investment trust with a demonstrated performance history of delivering superior and dependable returns by successfully managing, buying, selling, developing and redeveloping attractive real estate properties in targeted U.S. markets. As of December 31, 2022, UDR owned or had an ownership position in 58,390 apartment homes including 554 homes under development. For over 50 years, UDR has delivered long-term value to shareholders, the best standard of service to residents and the highest quality experience for associates.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230316005657/en/

UDR, Inc.
Trent Trujillo
[email protected]
720-283-6135

Source: UDR, Inc.

You May Also Be Interested In

• Mandela Digital Opens Mandela Dollar Early Access Applications on Nelson Mandela Day
• World War II Fighter Wreck of America's Top Ace Recovered from Jungles of Papua New Guinea
• REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting